Korea Joongang Daily
Korea JoongAng Daily

Samsung Bioepis starts selling Byooviz in U.S.

Samsung Bioepis launched Byooviz, its biosimilar version of the eye treatment Lucentis, in the U.S., the company said Friday.

2022-06-03

Byooviz, a Samsung Bioepis biosimilar, approved in the EU

Byooviz, a Samsung Bioepis biosimilar referencing ophthalmology treatment Lucentis, was approved for sale in the EU, the company said Monday.

2021-08-23